Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06752681 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Day One Biopharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 254
- Enrollment target
- 12
- Study locations
NCT06752681 is a Phase 1 study of Advanced or Metastatic Solid Tumors that is actively recruiting participants, run by Day One Biopharmaceuticals. The registered enrollment target is 254 participants, above the 224-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (13% higher). The trial reports 12 study locations across 10 states.
The verdict
NCT06752681, a Phase 1 study of Advanced or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Day One Biopharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 254 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in participants with advanced or metastatic solid tumors. The study comprises of 2 phases: Phase 1a dose escalation where participants will be administered DAY301 at escalating dose levels to assess safety and tolerability, and to determine the maximum tolerated dose (MTD) and/or the recommended dose (RD); In Phase 1b dose expansion, DAY301 will be evaluated in dose expansion cohorts.
Conditions Studied
Interventions
- DRUG DAY301
Study Locations (12)
Florida
- Site: 001-063 - Lake Mary
- Site: 001-064 - Sarasota
Texas
- Site: 001-069 - Houston
- Site: 001-057 - San Antonio
Connecticut
- Site: 001-058 - New Haven
Indiana
- Site: 001-060 - Indianapolis
Michigan
- Site: 001-059 - Grand Rapids
New York
- Site: 001-039 - New York
Oklahoma
- Site: 001-073 - Oklahoma City
Tennessee
- Site: 001-065 - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06752681
The ClinicalTrials.gov registry entry for NCT06752681 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 224-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (13% higher). The listed sponsor is Day One Biopharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which DAY301 is the first listed.
NCT06752681 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Florida, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06752681 about?
NCT06752681 is a clinical study titled "To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors". This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in participants with advanced or metastatic solid tumors. The study comprises of 2 phases: Phase 1a dose escalation where participa...
What is the current status of trial NCT06752681?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 254 participants. The study started on 2024-11-18. Estimated completion is 2028-12.
What conditions does trial NCT06752681 study?
This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT06752681?
The interventions under investigation include: DAY301 (DRUG).
Who is sponsoring clinical trial NCT06752681?
This trial is sponsored by Day One Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06752681 being conducted?
This trial has 12 study locations across Connecticut, Florida, Indiana, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.